



Sickle Cell & Thalassaemia Support Project

# Annual Report

## 2023-2024



Company No: 3575079  
Charity No: 1077687

[sctsp.org.uk](https://sctsp.org.uk)



# Chairman's Remarks

Another year gone, and another opportunity to say thank you to everyone for their support and contributions over the past year. A big thanks also to our sponsors, whose support has meant we were able to reach out more to those individuals and families in need . Everyone's efforts - however small, is much appreciated - and makes a difference. We are trying to respond more to those we aim to serve and hope, moving forward, that service users can benefit even more from the services we provide. Finally, my particular thanks to the staff and Board Members for their efforts and enduring commitment to the organisation.

## Our Impact

The organisation was established in 1990 to support individuals and families affected by Sickle Cell and Thalassaemia- we have maintained our business and have been working alongside healthcare professionals, parents and people living with the conditions to raise awareness of the disorders. Our main aim is to support those living with Sickle Cell and Thalassaemia, empowering them to build resilience to achieve their full potential.

From April 2023-March 2024, we received and processed 723 unusual blood results.

	Wolverhampton	Walsall	Dudley
Antenatal	242	156	124
Neonatal	136	65	

To learn more about this process, please visit <https://www.nhs.uk/pregnancy> and search for screening for sickle. We have supported service users with their health plans and we have worked with schools to provide a new or reviewed care plan for 160 children. We have also supported many affected adults, children and their families with their wellbeing through multiple activities and events.

Number of Sickle Cell & Thalassaemia Clients:

152 Adults, 179 Children

Areas of support:


Wolverhampton, Walsall, Dudley and the surrounding areas.

**Services available:**  
The project collaborates with the NHS to support sickle cell and thalassaemia screening. Counselling ensures individuals receive accessible information about haemoglobinopathies, focusing on genetic, health and psychological support while respecting cultural backgrounds.

- Key Services include:
- One-to-one counselling for risk factors
  - Annual care plans and assessments for children and adults
  - Home, hospital and community visits
  - Referrals to relevant agencies for additional support

The project also provides training for healthcare professionals, raises awareness in schools, and promotes community education to enhance understanding and management of these conditions.

## Finances





# National Grid

Helping families stay warm during winter



nationalgrid

The Sickle Cell & Thalassaemia Support Project received funding from the National Grid ([nationalgrid.co.uk](https://nationalgrid.co.uk)) to support our service users to stay warm throughout winter. This project ran from January to March 2024 and supported many families affected by Sickle Cell and Thalassaemia blood disorders.

The project aimed to provide vital resources and support to individuals and families affected by sickle cell and thalassaemia blood disorders to keep their homes warm and energy bills low. On Tuesday 6th February, we held an event at Bob Jones Community Hub with organisations such as Act-on Energy, LEAP, Severn Trent and Wolverhampton City Council providing free support and advice.

As part of this project, we were able to distribute nearly 100 warm packs which included items such as electric blankets, heaters, draft excluders, duvets, and radiator reflectors. These resources provided much needed warm and comfort to those affected by the conditions.



# National Lottery Community Fund

Empowering Parents and Young People



The Sickle Cell & Thalassaemia Support Project received funding from the National Lottery Community Fund ([tnlcommunityfund.org.uk](https://tnlcommunityfund.org.uk)) to empower parents and young people impacted by Sickle Cell and Thalassaemia blood disorders.

We provided a variety of workshops for parents around building self-confidence, developing a positive mindset and managing anxiety and worries. Living with a serious blood disorder can be challenging for both the affected individual and their families. Supporting parents with their wellbeing meant they were in a better position to support their children.

We were also able to provide activities to support young peoples wellbeing such as a tour and storytelling session at Wolverhampton Grand Theatre and a Sports Day.





## Activities

We are immensely grateful for all the support we received this year from Collins Aerospace in Wolverhampton. Over the year, the Sickie Cell & Thalassaemia Support Project team and the families they support have been able to get involved in a variety of events and activities.

Collins Aerospace Family Fun Day was a great event with plenty of free activities to get involved with. The Sickie Cell & Thalassaemia Support Project team along with a handful of families they support were able to enjoy face painting, bouncy castles, free ice cream and much more.

Collins Aerospace have involved the young people supported by our project in STEM activities including a STEM day on their site and a STEM careers talk at Graiseley Family Hub in Wolverhampton. These events provides a unique opportunity to explore the world of science and engineering and careers available.

During Black History Month, we had the privilege of joining an inspiring gathering featuring Former Heavyweight World Champion Frank Bruno MBE. Frank Bruno spoke about his mental health journey and how he manages it on a day-to-day basis. We were also able to talk at this event, raising awareness of Sickie Cell and Thalassaemia blood disorders.

Just before Easter, Collins Aerospace donated 100 Easter Eggs for the families we support. We ran an Easter Art Event allowing young people to get involved with a variety of creative and fun activities. Every child who attended enjoyed leaving with an Easter Egg to enjoy over Easter.



## Fundraising

We were grateful for all the support received by Collins Aerospace fundraising for the Sickie Cell & Thalassaemia Support Project.

Collins Aerospace were the main sponsor for Wolverhampton Krazy Races in August 2023, raising money for the project as part of this event.

Collins Aerospace also greatly supported our Christmas Donations Event. This included providing us with the funds by buy food and toiletries to help support families affected by Sickie Cell and Thalassaemia stay well over Christmas. They also donated a variety of clothes for adults and children which we were able to hand out at our event.





# The New Black Film Collective

Media project for young people affected by Sickle Cell Disease



With funding from the BBC Children in Need's We Move Fund: Youth Social Action, The New Black Film Collective launched their Sickle Cell Warriors project to give young people affected by sickle cell the chance to make an impact through a media project.

In partnership with The New Black Film Collective, we accompanied young people supported by the Sickle Cell & Thalassaemia Support Project at a series of events including a research trip in London and speaking on WCR FM, a local radio station in Wolverhampton.




## Cash For Kids

Bringing smiles to young people



Cash for Kids is a grant-giving charity helping the children that need it most across the UK. Their mission is to improve the lives of disadvantaged children and young people in our communities who are affected by poverty, illness, neglect or have additional needs.

On Tuesday 29th August 2023, a handful of the young people we support and some of their parents had an unforgettable visit to Wolverhampton Grand Theatre. A tour took place for older children and a story telling session for younger ones. Thanks to Cash for Kids, we were able to give 50 young people a gift voucher, allowing them to do something or buy something they wouldn't have usually had the opportunity to do. Some young people chose to spend their vouchers on clothes and back-to-school stationary of their choice, others chose to enjoy a meal at a restaurant with their family.





# Cat's Great North Run

Raising money for our hardship fund

On Sunday 10th September 2023, Cat participated in the Great North Run. She took it upon herself to run in the Great North Run with the goal of raising £500 for our 'Hardship Fund'. This Fund plays a crucial role in providing direct support for families when they find themselves at their most vulnerable.

We understand that times have been tough for everyone, but we are truly touched by the outpouring of support from our community. Thanks to your contributions, Cat not only completed the Great North Run in an impressive 2 hours and 11 minutes but also raised an astounding total of £1670 for the Sickle Cell & Thalassaemia Support Project.



## Testimonials

The staff at the project are amazing very friendly, welcoming and supportive. I would like to say you are doing a would job and thanks for supporting my family and I throughout the years.- **Wolverhampton Adult**

(National Grid Project) Yes, it was really helpful. Most especially this time that things are expensive. It was a great relief support.- **Walsall Parent**

I really thank you for all that you do. It was extremely appreciated- **Walsall Adult**

(Cash for Kids) I am now more confident I will be able to purchase appropriate clothing for the colder weather. It will really help with the cost. My finances are very stretched at the moment.- **Dudley Parent**

## Our Supporters

**nationalgrid**



COMPANY REGISTERED NUMBER: 03575079 (England and Wales)

CHARITY REGISTERED NUMBER: 1077687

SICKLE CELL AND THALASSAEMIA SUPPORT  
PROJECT (WOLVERHAMPTON)

REPORT OF THE DIRECTORS AND

FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31ST MARCH 2024

**SICKLE CELL AND THALASSAEMIA SUPPORT PROJECT (WOLVERHAMPTON)**

**CONTENTS OF THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31ST MARCH 2024**

	<b>Page</b>
<b>Company Information</b>	<b>1</b>
<b>Report of the Directors and Trustees</b>	<b>2</b>
<b>Statement of Trustees' responsibilities</b>	<b>4</b>
<b>Independent examiner's report</b>	<b>5</b>
<b>Statement of financial activities</b>	<b>6</b>
<b>Balance sheet</b>	<b>8</b>
<b>Notes to the financial statements</b>	<b>9</b>



**SICKLE CELL AND THALASSAEMIA SUPPORT PROJECT (WOLVERHAMPTON)**

**COMPANY INFORMATION  
FOR THE YEAR ENDED 31ST MARCH 2024**

**DIRECTORS/TRUSTEES:** C R Crosdale  
D McIntosh  
D A McIntosh  
Dr D Kalra  
L Bell  
L T Mooruth  
D C Smith  
A A Ezomon (appointed 22 September 2023)

**SECRETARY:** S Herian

**REGISTERED OFFICE:** Paycare House  
1st Floor  
George Street  
Wolverhampton  
WV2 4DX

**REGISTERED NUMBER:** 03575079 (England and Wales)

**REGISTERED CHARITY  
NUMBER:** 1077687

**INDEPENDENT EXAMINER:** Neil Harris FCA BSc (Hons)  
Cygnat Accounting Limited  
37 Rossell Drive  
Stapleford  
Nottingham, NG9 7EG

**BANKERS:** Lloyds Bank Plc  
37 Queen Square  
Wolverhampton  
WV1 1TL

**SOLICITORS:** Wall James Chappell  
15-23 Hagley Road  
Stourbridge  
DY8 1QW

## **SICKLE CELL AND THALASSAEMIA SUPPORT PROJECT (WOLVERHAMPTON)**

### **REPORT OF THE DIRECTORS AND TRUSTEES FOR THE YEAR ENDED 31ST MARCH 2024**

The directors, who are also trustees of the charity, present their report with the financial statements of the company for the year ended 31st March 2024. The directors have adopted the provisions of the Statement of Recommended Practice (SORP) "Accounting and Reporting by Charities" (FRS 102) in preparing the annual report and financial statements.

#### **PRINCIPAL ACTIVITIES**

The principal charitable activities of the company in the year under review were those to provide relief of poverty, sickness and distress, and enhancement of life, to those affected by the disorders Sickle Cell Disease and Thalassaemia, living within the West Midlands and surrounding areas. Those so affected are predominantly from African, Caribbean, Mediterranean and Asian communities. In 2016 the charity had expanded its activities to include working with families with complex and multiple needs, in order to promote, strengthen and improve their life chances.

#### **DIRECTORS AND TRUSTEES**

The directors and trustees during the year under review were:

C R Crosdale  
D McIntosh  
D A McIntosh  
Dr D Kalra  
L Bell  
L T Mooruth  
D C Smith  
A A Ezomon (appointed 22 September 2023)

#### **COMPANY STATUS**

The company is limited by guarantee and is a registered charity (Registered No 1077687). This report has been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

#### **OBJECTS AND REVIEW OF THE COMPANY**

The report sets out activities and achievements of the charity for 2023/2024. The organisation was formed in September 1990 and founded as a charity in 1996. The objects of the charity allow the trustees to develop comprehensively and consistently high quality services for users, their carers, families and professionals who interact with them, within the Wolverhampton and surrounding areas notably Black Country and Staffordshire.

The Trustees support a number of activities in pursuant of its objects. These are as follows:

- To offer counselling and screening to those individuals affected by Sickle Cell or Thalassaemia.
- To provide advice, support and guidance to affected individuals.
- To increase awareness by developing educational materials and promotion of raising awareness activities.
- To support both universal and voluntary screening programmes.
- To develop robust community development activities to promote and support the affected communities.
- To strengthen and support families with complex and challenging needs.

The Trustees meet every three months to review overall performance of the charity and to give strategic guidance. The directors/trustees review, and consider, the charitable company's reserves in the context of risks and funding. In setting a reserves policy the directors aim to establish reasonable but not absolute protection against risks and to balance this with the need to deploy resources in pursuit of the company's charitable objectives. Reserves are intended to:

- 1) Provide protection for most fluctuations in income and expenditure
- 2) Fund future investment needs and non-recurrent premises costs

#### **Operational Costs**

With the changes that have taken place during the year it has necessitated a review of the Reserve Policy in relation to operational activities. It is now proposed that the reserves target should at least cover eight months



## SICKLE CELL AND THALASSAEMIA SUPPORT PROJECT (WOLVERHAMPTON)

### REPORT OF THE DIRECTORS AND TRUSTEES FOR THE YEAR ENDED 31ST MARCH 2024

of operation including redundancy cost. The new proposed figure is £225,000. The Reserves at the end of the financial year 2024 were £733,112 (2023: £678,261).

#### Rent Costs

SCTSP are currently residing in a building paying reduced service charge. This may not be a long-lasting agreement and we cannot be certain in any way shape or form that the management structure of the owners of the building will not change and thereby begin to charge rent that will cause major disruption to the operational activities of SCTSP. With this in mind it is our proposal that we begin to build a reserve in the accounts to cater for this anomaly. We are currently paying service charge of about £9,750 per annum and we would expect that we probably should be paying rent somewhere in the region of £28,000 per annum. It is therefore proposed that in this year's accounts we set aside £48,000 in designated reserves.

The majority of the charitable company's funding is from NHS contracts which normally are renewable on a 1-2 year period. Additional funding is obtained from donations by supporters of the charity, however given the difficult economic climate, like many charities we have seen a reduction in this income, however we are still appreciative of those who continue to collect donations on behalf of the charity. We also recognise that those who make such donations are keen to see our service users directly benefit from their efforts and to this end the Trustees have decided that the majority of these funds will go towards the Hardship Fund established by the charity. Currently a provision of £5,000 has been set aside and will be drawn down within each year's expenditure depending on numbers of individuals identified to receive such support.

The charity has invested surplus funds with the objective to generate funds through capital growth. The funds are managed by Milsted Langdon and are monitored by the Finance Sub Committee with regular reports to the Board. A cautious approach has been taken to risk over the period to reflect the volatility in the market that can occur. With the increase in income the organisation will review its investment portfolio with this in mind.

The Trustees regularly review the finances of the charity and are pleased that a satisfactory independent accountant's examination has been achieved.

#### PUBLIC BENEFIT

All the charity's activities are aimed at supporting local individuals affected by sickle cell and thalassaemia and families experiencing challenges. In developing activities and delivering services, the directors have taken account of the guidance published by the Charity Commission on public benefit.

#### DEFINED BENEFIT PENSION SCHEME

A full actuarial valuation was carried out as at 31 March 2022, the results of which are shown in note 9 of the financial statements. With respect to this liability Wolverhampton City Council has agreed to act as a guarantor towards this liability. However, the recent actuarial valuation, which shows a current liability of £512,000, as with previous years, the Trustees will continue to be mindful of this liability within its overall reserve policy.

#### RISK MANAGEMENT

The trustees have considered the major risks the charity faces. The charity's system of internal controls is designed to provide reasonable but not absolute assurance against misstatement or loss. The trustees are satisfied that the systems in place mitigate the charity's exposure to the major risks.

#### ON BEHALF OF THE BOARD:



L Bell - Director/Trustee



C R Crosdale - Director/Trustee

Date: 22.10.2024

The notes form part of these financial statements

**SICKLE CELL AND THALASSAEMIA SUPPORT PROJECT (WOLVERHAMPTON)**

**STATEMENT OF TRUSTEES' RESPONSIBILITIES  
FOR THE YEAR ENDED 31ST MARCH 2024**

The trustees, who are also the directors of Sickle Cell and Thalassaemia Support Project (Wolverhampton) for the purpose of company law, are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company Law requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that year.

In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.

The trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.



**SICKLE CELL AND THALASSAEMIA SUPPORT PROJECT (WOLVERHAMPTON)**

**INDEPENDENT EXAMINER'S REPORT  
FOR THE YEAR ENDED 31ST MARCH 2024**

I report to the trustees on my examination of the financial statements of Sickle Cell And Thalassaemia Support Project (Wolverhampton) (the charity) for the year ended 31 March 2024.

**Responsibilities and basis of report**

As the trustees of the charity (and also its directors for the purposes of company law) you are responsible for the preparation of the financial statements in accordance with the requirements of the Companies Act 2006 (the 2006 Act).

Having satisfied myself that the financial statements of the charity are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of the charity's financial statements carried out under the Charities Act (the Act). In carrying out my examination I have followed all the applicable Directions given by the Charity Commission under the Act.

**Independent examiner's statement**

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the charity as required by section 386 of the 2006 Act; or
2. the financial statements do not accord with those records; or
3. the financial statements do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
4. the financial statements have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with Section 1A "Small Entities" of Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland".

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.



.....  
Neil Harris FCA BSc (Hons)

Cygnat Accounting Limited  
37 Rossell Drive  
Stapleford  
Nottingham  
NG9 7EG

Dated: 30/04/24

**SICKLE CELL AND THALASSAEMIA SUPPORT PROJECT (WOLVERHAMPTON)**

**STATEMENT OF FINANCIAL ACTIVITIES (INCLUDING INCOME AND EXPENDITURE ACCOUNT)  
FOR THE YEAR ENDED 31ST MARCH 2024**

	Notes	Unrestricted Funds £	Restricted Funds £	Total Funds 2024 £	Total Funds 2023 £
<b>INCOME FROM:</b>					
Donations and other income		90,001	-	90,001	118,744
Investment income		18,593	-	18,593	931
Charitable activities:					
Service level agreements from:					
Wolverhampton Clinical Commissioning Group		-	115,720	115,720	113,674
Dudley Clinical Commissioning Group		-	16,962	16,962	16,630
Walsall Healthcare NHS Trust		-	50,773	50,773	50,072
Staffordshire CC – FSS/FIP/PP/Sapling		-	-	-	63,862
<b>TOTAL INCOME</b>		<u>108,594</u>	<u>183,455</u>	<u>292,049</u>	<u>363,913</u>
<b>EXPENDITURE ON:</b>					
Raising funds	1	249	10,732	10,981	11,331
Charitable activities	2	<u>6,425</u>	<u>224,109</u>	<u>230,534</u>	<u>235,861</u>
<b>TOTAL EXPENDITURE</b>		<u>6,674</u>	<u>234,841</u>	<u>241,515</u>	<u>247,192</u>
Net incoming / (expenditure) before gain or loss on investments		101,920	(51,386)	50,534	116,721
Unrealised gain/(loss) on investments		4,317	-	4,317	(5,688)
Balances brought forward as at 1 April 2023		<u>428,906</u>	<u>249,355</u>	<u>678,261</u>	<u>567,228</u>
Balances carried forward as at 31 March 2024		<u>535,143</u>	<u>197,969</u>	<u>733,112</u>	<u>678,261</u>

The statement of financial activities includes all gains and losses recognised in the year.

All income and expenditure derive from continuing activities.

The statement of financial activities also complies with the requirements for an income and expenditure account under the Companies Act 2006.

The notes form part of these financial statements



**SICKLE CELL AND THALASSAEMIA SUPPORT PROJECT (WOLVERHAMPTON)**

**NOTES TO THE STATEMENT OF FINANCIAL ACTIVITIES  
FOR THE YEAR ENDED 31ST MARCH 2024**

	Unrestricted Funds £	Restricted Funds £	Total Funds 2024 £	Total Funds 2023 £
<b>1 RAISING FUNDS</b>				
Wages	157	7,687	7,844	7,986
Social Security	10	473	483	577
Pensions	24	1,162	1,186	1,135
Repairs & maintenance	7	137	144	97
Telephone	7	336	343	550
Sundry expenses	6	111	117	78
Postage, printing & stationery	6	110	116	143
Rent & service charge	24	447	471	471
Insurance	3	170	173	188
Depreciation - office equipment	-	4	4	14
Bank charges	5	95	100	92
	<u>249</u>	<u>10,732</u>	<u>10,981</u>	<u>11,331</u>
<b>2 CHARITABLE ACTIVITIES</b>				
Wages	1,490	147,556	149,046	151,734
Social Security	184	8,996	9,180	10,962
Pensions	451	22,087	22,538	21,573
Staff training	-	1,435	1,435	885
Travelling	94	1,789	1,883	1,619
Repairs & maintenance	137	2,605	2,742	1,847
Social hardship donation	1,240	-	1,240	605
Social support	-	12,736	12,736	-
Consultancy service development	-	1,500	1,500	2,100
Subscriptions	2,085	-	2,085	1,800
Telephone	130	6,379	6,509	10,448
Sundry expenses	111	2,109	2,220	1,481
Postage, printing & stationery	110	2,089	2,199	2,716
Rent & service charge	179	8,770	8,949	8,949
Insurance	66	3,225	3,291	3,577
Depreciation - office equipment	4	81	85	257
Support costs:				
Board expenses	6	117	123	100
Accountancy	77	1,473	1,550	2,160
Professional fees	61	1,162	1,223	13,048
	<u>6,425</u>	<u>224,109</u>	<u>230,534</u>	<u>235,861</u>

The notes form part of these financial statements

**SICKLE CELL AND THALASSAEMIA SUPPORT PROJECT (WOLVERHAMPTON)**

**BALANCE SHEET  
31ST MARCH 2024**

		2024		2023	
	Notes	£	£	£	£
<b>Fixed assets</b>					
Tangible assets	4		504		593
<b>Current assets</b>					
Debtors	5	7,190		1,020	
Investments	6	52,924		48,607	
Cash at bank and in hand		<u>760,334</u>		<u>715,201</u>	
		820,448		764,828	
<b>Creditors: Amounts falling due within one year</b>	7	<u>(2,840)</u>		<u>(2,160)</u>	
<b>Net current assets</b>			<u>817,608</u>		<u>762,668</u>
<b>Total assets less current liabilities</b>			818,112		763,261
<b>Creditors: Amounts falling due within one year</b>	8		<u>85,000</u>		<u>85,000</u>
<b>Net assets</b>			<u>733,112</u>		<u>678,261</u>
<b>Income funds</b>					
Unrestricted funds:					
General funds		455,143		348,906	
Designated funds		<u>80,000</u>		<u>80,000</u>	
		535,143		428,906	
Restricted funds		<u>197,969</u>		<u>249,355</u>	
<b>Total income funds</b>			<u>733,112</u>		<u>678,261</u>


The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31st March 2024.


The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year ended 31st March 2024 in accordance with Section 476 of the Companies Act 2006.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the Board of Trustees on 22/10/24 and were signed on its behalf by:

  
 L Bell  
 Director/Trustee

  
 C R Crosdale  
 Director/Trustee

Company registration number 03575079

## **SICKLE CELL AND THALASSAEMIA SUPPORT PROJECT (WOLVERHAMPTON)**

### **NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH 2024**

#### **1. Accounting policies**

##### **Charity information**

Sickle Cell and Thalassaemia Support Project (Wolverhampton) is a private company limited by guarantee incorporated in England and Wales. The registered office is Paycare House, 1st Floor, George Street, Wolverhampton, WV2 4DX. The members of the company are the trustees names on page 1. In the event of the charity being wound up, the liability in respect of the guarantee is limited to £1 per member of the charity.

##### **Accounting convention**

The financial statements have been prepared under the historical cost convention and in accordance with the provisions of Section 1A "Small Entities" of Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", the Charities Act, the Companies Act 2006 and the Statement of Recommended Practice: "Accounting and Reporting by Charities" (FRS 102) with the exception of accounting for the deficit on the defined benefit pension scheme, for which provision has been made as set out below and in note 9.

The financial statements are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £.

##### **Charitable funds**

Unrestricted funds are available for use at the discretion of the trustees in furtherance of their charitable objectives.

Designated funds comprise unrestricted funds that have been set aside by the trustees for particular purposes. The aim and use of each designated fund is set out in the notes to the financial statements.

Restricted funds are subject to specific conditions by donors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.

##### **Income**

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Gifts in kind donated for distribution are included at valuation and recognised as income when they are distributed to the projects. Gifts donated for resale are included as income when they are sold. Donated facilities are included at the value to the charity where this can be quantified and a third party is bearing the cost. No amounts are included in the financial statements for services donated by volunteers.

##### **Expenditure**

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement, and the amount of the obligation can be measured reliably.

Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges are allocated on the portion of the asset's use.



## SICKLE CELL AND THALASSAEMIA SUPPORT PROJECT (WOLVERHAMPTON)

### NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH 2024

#### 1. Accounting policies (continued)

All expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all costs related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with use of the resources.

Fund-raising costs are those incurred in seeking voluntary contributions and do not include the costs of disseminating information in support of the charitable activities. Support costs are costs incurred directly in support of expenditure on the objects of the charity and include project management carried out at headquarters. Management and administration costs are those incurred in connection with the administration of the charity and compliance with constitutional and statutory requirements.

#### **Tangible fixed assets**

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Plant and machinery	- 25% on cost
Fixtures and fittings	- 15% & 25% on reducing balance

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in the statement of financial activities.

#### **Investments**

Investments are stated at market value at the balance sheet date. The SOFA includes the net gains or losses arising on revaluation throughout the year.

#### **Pensions**

The company operates a defined benefit pension scheme which provides benefits based on final pensionable pay. The scheme is administered by the West Midlands Pension Fund, and the assets are held independently of the finances of the company. The most recent full actuarial valuation was carried out at 31 March 2022. The projected valuation deficit in the scheme at 31 March 2022 was £512,000. The Board has considered this situation and feels that because of the age of the work force this deficit can be eliminated over a period of time and currently a total provision of £85,000 has been made to date in these accounts.

#### **Restricted Funds**

Monies received as grants for particular purposes are held as separate funds and are credited to the Statement of Financial Activities when costs of the particular relevant projects are incurred.

#### **Leases**

Rentals payable under operating leases, including any lease incentives received, are charged to income on a straight line basis over the term of the relevant lease.

**SICKLE CELL AND THALASSAEMIA SUPPORT PROJECT (WOLVERHAMPTON)**

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31ST MARCH 2024**

**2. STAFF COSTS**

	2024 £	2023 £
Wages and salaries	156,890	159,720
Social security costs	9,663	11,539
Other pension costs	<u>23,724</u>	<u>22,708</u>
	<u>190,277</u>	<u>193,967</u>

The average monthly number of employees during the year was as follows:

	2024	2023
Charitable Workers	<u>5</u>	<u>5</u>

There are no employees who received total emoluments of more than £60,000.

**3. OPERATING PROFIT/(LOSS)**

	2024 £	2023 £
Depreciation - owned assets	<u>89</u>	<u>270</u>
Directors' emoluments and other benefits etc	<u>-</u>	<u>-</u>

**4. TANGIBLE FIXED ASSETS**

	Plant and machinery £	Fixtures and fittings £	Total £
<b>Cost</b>			
At 1st April 2023	23,824	13,391	37,215
Additions	-	-	-
Disposals	<u>-</u>	<u>-</u>	<u>-</u>
At 31st March 2024	<u>23,824</u>	<u>13,391</u>	<u>37,215</u>
<b>Depreciation</b>			
At 1st April 2023	23,824	12,798	36,622
Charge for year	-	89	89
Eliminated on disposals	<u>-</u>	<u>-</u>	<u>-</u>
At 31st March 2024	<u>23,824</u>	<u>12,887</u>	<u>36,711</u>
<b>Net book value</b>			
At 31st March 2024	<u>-</u>	<u>504</u>	<u>504</u>
At 31st March 2023	<u>-</u>	<u>593</u>	<u>593</u>

**SICKLE CELL AND THALASSAEMIA SUPPORT PROJECT (WOLVERHAMPTON)**

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31ST MARCH 2024**

**5. DEBTORS: AMOUNTS FALLING  
DUE WITHIN ONE YEAR**

	2024 £	2023 £
Prepayments and accrued income	<u>7,190</u>	<u>1,020</u>

**6. CURRENT ASSET INVESTMENTS**

	2024 £	2023 £
Architas MA Passive Moderate S Acc	<u>52,924</u>	<u>48,607</u>

**7. CREDITORS: AMOUNTS FALLING  
DUE WITHIN ONE YEAR**

	2024 £	2023 £
Social security and other tax	-	-
Accruals and deferred income	<u>2,840</u>	<u>2,160</u>
	<u>2,840</u>	<u>2,160</u>

**8. CREDITORS: AMOUNTS FALLING  
DUE AFTER MORE THAN ONE YEAR**

	2024 £	2023 £
Provision for defined pension scheme deficit (see note 9)	<u>85,000</u>	<u>85,000</u>

**9. PENSION SCHEME**

	2024 £	2023 £
Value of scheme assets and liabilities		
Market value of assets	820,000	820,000
Present value of scheme liabilities	<u>(1,332,000)</u>	<u>(1,332,000)</u>
Pension scheme deficit	<u>(512,000)</u>	<u>(512,000)</u>

The above is based on a valuation at 31 March 2022. Provision of £85,000 has been made towards the above deficit.



**SICKLE CELL AND THALASSAEMIA SUPPORT PROJECT (WOLVERHAMPTON)**

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31ST MARCH 2024**

**10. OPERATING LEASE COMMITMENTS**

At the reporting end date the charity had outstanding commitments for future minimum lease payments under non-cancellable operating leases, which fall due as follows:

	2024 £	2023 £
Within one year	-	-
Between two and five years	<u>-</u>	<u>-</u>
	<u>-</u>	<u>-</u>

**11. ANALYSIS OF NET ASSETS BETWEEN FUNDS**

	Fixed Assets £	Other Net Assets £	Total Net Assets £
Unrestricted Funds:			
General Funds	-	455,143	455,143
Designated Funds	<u>-</u>	<u>80,000</u>	<u>80,000</u>
	-	535,143	535,143
Restricted Funds	<u>504</u>	<u>197,465</u>	<u>197,969</u>
	<u>504</u>	<u>732,608</u>	<u>733,112</u>

**12. RESTRICTED FUNDS**

<b>Fund</b>	<b>Purpose of Fund</b>	<b>Reason for Restriction</b>
Wolverhampton CCG	Support the antenatal and newborn screening programme and provide counselling and support to those affected	Wolverhampton residents only
Dudley CCG	Support affected children with long term conditions to manage their condition through various social and community interventions	Dudley residents only
Walsall Healthcare NHS Trust	Support the antenatal and newborn screening programme and provide counselling and support to those affected	Walsall residents only

**COMPANY REGISTERED NUMBER: 03575079 (England and Wales)**

**CHARITY REGISTERED NUMBER: 1077687**

**SICKLE CELL AND THALASSAEMIA SUPPORT  
PROJECT (WOLVERHAMPTON)**

**REPORT OF THE DIRECTORS AND**

**FINANCIAL STATEMENTS**

**FOR THE YEAR ENDED 31ST MARCH 2024**

# **SICKLE CELL AND THALASSAEMIA SUPPORT PROJECT (WOLVERHAMPTON)**

## **CONTENTS OF THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH 2024**

	<b>Page</b>
<b>Company Information</b>	<b>1</b>
<b>Report of the Directors and Trustees</b>	<b>2</b>
<b>Statement of Trustees' responsibilities</b>	<b>4</b>
<b>Independent examiner's report</b>	<b>5</b>
<b>Statement of financial activities</b>	<b>6</b>
<b>Balance sheet</b>	<b>8</b>
<b>Notes to the financial statements</b>	<b>9</b>



**SICKLE CELL AND THALASSAEMIA SUPPORT PROJECT (WOLVERHAMPTON)**

**COMPANY INFORMATION  
FOR THE YEAR ENDED 31ST MARCH 2024**

<b>DIRECTORS/TRUSTEES:</b>	C R Crosdale D McIntosh D A McIntosh Dr D Kalra L Bell L T Mooruth D C Smith A A Ezomon (appointed 22 September 2023)
<b>SECRETARY:</b>	S Herian
<b>REGISTERED OFFICE:</b>	Paycare House 1st Floor George Street Wolverhampton WV2 4DX
<b>REGISTERED NUMBER:</b>	03575079 (England and Wales)
<b>REGISTERED CHARITY NUMBER:</b>	1077687
<b>INDEPENDENT EXAMINER:</b>	Neil Harris FCA BSc (Hons) Cygnet Accounting Limited 37 Rossell Drive Stapleford Nottingham, NG9 7EG
<b>BANKERS:</b>	Lloyds Bank Plc 37 Queen Square Wolverhampton WV1 1TL
<b>SOLICITORS:</b>	Wall James Chappell 15-23 Hagley Road Stourbridge DY8 1QW

## **SICKLE CELL AND THALASSAEMIA SUPPORT PROJECT (WOLVERHAMPTON)**

### **REPORT OF THE DIRECTORS AND TRUSTEES FOR THE YEAR ENDED 31ST MARCH 2024**

The directors, who are also trustees of the charity, present their report with the financial statements of the company for the year ended 31st March 2024. The directors have adopted the provisions of the Statement of Recommended Practice (SORP) "Accounting and Reporting by Charities" (FRS 102) in preparing the annual report and financial statements.

#### **PRINCIPAL ACTIVITIES**

The principal charitable activities of the company in the year under review were those to provide relief of poverty, sickness and distress, and enhancement of life, to those affected by the disorders Sickle Cell Disease and Thalassaemia, living within the West Midlands and surrounding areas. Those so affected are predominantly from African, Caribbean, Mediterranean and Asian communities. In 2016 the charity had expanded its activities to include working with families with complex and multiple needs, in order to promote, strengthen and improve their life chances.

#### **DIRECTORS AND TRUSTEES**

The directors and trustees during the year under review were:

C R Crosdale

D McIntosh

D A McIntosh

Dr D Kalra

L Bell

L T Mooruth

D C Smith

A A Ezomon (appointed 22 September 2023)

#### **COMPANY STATUS**

The company is limited by guarantee and is a registered charity (Registered No 1077687). This report has been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

#### **OBJECTS AND REVIEW OF THE COMPANY**

The report sets out activities and achievements of the charity for 2023/2024. The organisation was formed in September 1990 and founded as a charity in 1996. The objects of the charity allow the trustees to develop comprehensively and consistently high quality services for users, their carers, families and professionals who interact with them, within the Wolverhampton and surrounding areas notably Black Country and Staffordshire.

The Trustees support a number of activities in pursuant of its objects. These are as follows:

- To offer counselling and screening to those individuals affected by Sickle Cell or Thalassaemia.
- To provide advice, support and guidance to affected individuals.
- To increase awareness by developing educational materials and promotion of raising awareness activities.
- To support both universal and voluntary screening programmes.
- To develop robust community development activities to promote and support the affected communities.
- To strengthen and support families with complex and challenging needs.

The Trustees meet every three months to review overall performance of the charity and to give strategic guidance. The directors/trustees review, and consider, the charitable company's reserves in the context of risks and funding. In setting a reserves policy the directors aim to establish reasonable but not absolute protection against risks and to balance this with the need to deploy resources in pursuit of the company's charitable objectives. Reserves are intended to:

- 1) Provide protection for most fluctuations in income and expenditure
- 2) Fund future investment needs and non-recurrent premises costs

#### **Operational Costs**

With the changes that have taken place during the year it has necessitated a review of the Reserve Policy in relation to operational activities. It is now proposed that the reserves target should at least cover eight months

## **SICKLE CELL AND THALASSAEMIA SUPPORT PROJECT (WOLVERHAMPTON)**

### **REPORT OF THE DIRECTORS AND TRUSTEES FOR THE YEAR ENDED 31ST MARCH 2024**

of operation including redundancy cost. The new proposed figure is £225,000. The Reserves at the end of the financial year 2024 were £733,112 (2023: £678,261).

#### **Rent Costs**

SCTSP are currently residing in a building paying reduced service charge. This may not be a long-lasting agreement and we cannot be certain in anyway shape or form that the management structure of the owners of the building will not change and thereby begin to charge rent that will cause major disruption to the operational activities of SCTSP. With this in mind it is our proposal that we begin to build a reserve in the accounts to cater for this anomaly. We are currently paying service charge of about £9,750 per annum and we would expect that we probably should be paying rent somewhere in the region of £28,000 per annum. It is therefore proposed that in this year's accounts we set aside £48,000 in designated reserves.

The majority of the charitable company's funding is from NHS contracts which normally are renewable on a 1-2 year period. Additional funding is obtained from donations by supporters of the charity, however given the difficult economic climate, like many charities we have seen a reduction in this income, however we are still appreciative of those who continue to collect donations on behalf of the charity. We also recognise that those who make such donations are keen to see our service users directly benefit from their efforts and to this end the Trustees have decided that the majority of these funds will go towards the Hardship Fund established by the charity. Currently a provision of £5,000 has been set aside and will be drawn down within each year's expenditure depending on numbers of individuals identified to receive such support.

The charity has invested surplus funds with the objective to generate funds through capital growth. The funds are managed by Milsted Langdon and are monitored by the Finance Sub Committee with regular reports to the Board. A cautious approach has been taken to risk over the period to reflect the volatility in the market that can occur. With the increase in income the organisation will review its investment portfolio with this in mind.

The Trustees regularly review the finances of the charity and are pleased that a satisfactory independent accountant's examination has been achieved.

#### **PUBLIC BENEFIT**

All the charity's activities are aimed at supporting local individuals affected by sickle cell and thalassaemia and families experiencing challenges. In developing activities and delivering services, the directors have taken account of the guidance published by the Charity Commission on public benefit.

#### **DEFINED BENEFIT PENSION SCHEME**

A full actuarial valuation was carried out as at 31 March 2022, the results of which are shown in note 9 of the financial statements. With respect to this liability Wolverhampton City Council has agreed to act as a guarantor towards this liability. However, the recent actuarial valuation, which shows a current liability of £512,000, as with previous years, the Trustees will continue to be mindful of this liability within its overall reserve policy.

#### **RISK MANAGEMENT**

The trustees have considered the major risks the charity faces. The charity's system of internal controls is designed to provide reasonable but not absolute assurance against misstatement or loss. The trustees are satisfied that the systems in place mitigate the charity's exposure to the major risks.

#### **ON BEHALF OF THE BOARD:**

.....  
**L Bell** - Director/Trustee

.....  
**C R Crosdale** - Director/Trustee

Date:

The notes form part of these financial statements



## **SICKLE CELL AND THALASSAEMIA SUPPORT PROJECT (WOLVERHAMPTON)**

### **STATEMENT OF TRUSTEES' RESPONSIBILITIES FOR THE YEAR ENDED 31ST MARCH 2024**

The trustees, who are also the directors of Sickle Cell and Thalassaemia Support Project (Wolverhampton) for the purpose of company law, are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company Law requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that year.

In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.

The trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

## **SICKLE CELL AND THALASSAEMIA SUPPORT PROJECT (WOLVERHAMPTON)**

### **INDEPENDENT EXAMINER'S REPORT FOR THE YEAR ENDED 31ST MARCH 2024**

I report to the trustees on my examination of the financial statements of Sickle Cell And Thalassaemia Support Project (Wolverhampton) (the charity) for the year ended 31 March 2024.

#### **Responsibilities and basis of report**

As the trustees of the charity (and also its directors for the purposes of company law) you are responsible for the preparation of the financial statements in accordance with the requirements of the Companies Act 2006 (the 2006 Act).

Having satisfied myself that the financial statements of the charity are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of the charity's financial statements carried out under the Charities Act (the Act). In carrying out my examination I have followed all the applicable Directions given by the Charity Commission under the Act.

#### **Independent examiner's statement**

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the charity as required by section 386 of the 2006 Act; or
2. the financial statements do not accord with those records; or
3. the financial statements do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
4. the financial statements have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with Section 1A "Small Entities" of Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland".

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.

.....  
Neil Harris FCA BSc (Hons)

Cygnnet Accounting Limited  
37 Rossell Drive  
Stapleford  
Nottingham  
NG9 7EG

Dated: .....

# SICKLE CELL AND THALASSAEMIA SUPPORT PROJECT (WOLVERHAMPTON)

## STATEMENT OF FINANCIAL ACTIVITIES (INCLUDING INCOME AND EXPENDITURE ACCOUNT) FOR THE YEAR ENDED 31ST MARCH 2024

	Notes	Unrestricted Funds £	Restricted Funds £	Total Funds 2024 £	Total Funds 2023 £
<b>INCOME FROM:</b>					
Donations and other income		90,001	-	<b>90,001</b>	118,744
Investment income		18,593	-	<b>18,593</b>	931
Charitable activities:					
Service level agreements from:					
Wolverhampton Clinical Commissioning Group		-	115,720	<b>115,720</b>	113,674
Dudley Clinical Commissioning Group		-	16,962	<b>16,962</b>	16,630
Walsall Healthcare NHS Trust		-	50,773	<b>50,773</b>	50,072
Staffordshire CC – FSS/FIP/PP/Sapling		-	-	<b>-</b>	63,862
<b>TOTAL INCOME</b>		<u>108,594</u>	<u>183,455</u>	<b><u>292,049</u></b>	<u>363,913</u>
<b>EXPENDITURE ON:</b>					
Raising funds	1	249	10,732	<b>10,981</b>	11,331
Charitable activities	2	<u>6,425</u>	<u>224,109</u>	<b><u>230,534</u></b>	<u>235,861</u>
<b>TOTAL EXPENDITURE</b>		<u>6,674</u>	<u>234,841</u>	<b><u>241,515</u></b>	<u>247,192</u>
Net incoming / (expenditure) before gain or loss on investments		101,920	(51,386)	<b>50,534</b>	116,721
Unrealised gain/(loss) on investments		4,317	-	<b>4,317</b>	(5,688)
Balances brought forward as at 1 April 2023		<u>428,906</u>	<u>249,355</u>	<b><u>678,261</u></b>	<u>567,228</u>
Balances carried forward as at 31 March 2024		<u>535,143</u>	<u>197,969</u>	<b><u>733,112</u></b>	<u>678,261</u>

The statement of financial activities includes all gains and losses recognised in the year.

All income and expenditure derive from continuing activities.

The statement of financial activities also complies with the requirements for an income and expenditure account under the Companies Act 2006.



# SICKLE CELL AND THALASSAEMIA SUPPORT PROJECT (WOLVERHAMPTON)

## NOTES TO THE STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 31ST MARCH 2024

	Unrestricted Funds £	Restricted Funds £	Total Funds 2024 £	Total Funds 2023 £
<b>1 RAISING FUNDS</b>				
Wages	157	7,687	<b>7,844</b>	7,986
Social Security	10	473	<b>483</b>	577
Pensions	24	1,162	<b>1,186</b>	1,135
Repairs & maintenance	7	137	<b>144</b>	97
Telephone	7	336	<b>343</b>	550
Sundry expenses	6	111	<b>117</b>	78
Postage, printing & stationery	6	110	<b>116</b>	143
Rent & service charge	24	447	<b>471</b>	471
Insurance	3	170	<b>173</b>	188
Depreciation - office equipment	-	4	<b>4</b>	14
Bank charges	<u>5</u>	<u>95</u>	<u><b>100</b></u>	<u>92</u>
	<u>249</u>	<u>10,732</u>	<u><b>10,981</b></u>	<u>11,331</u>
<b>2 CHARITABLE ACTIVITIES</b>				
Wages	1,490	147,556	<b>149,046</b>	151,734
Social Security	184	8,996	<b>9,180</b>	10,962
Pensions	451	22,087	<b>22,538</b>	21,573
Staff training	-	1,435	<b>1,435</b>	885
Travelling	94	1,789	<b>1,883</b>	1,619
Repairs & maintenance	137	2,605	<b>2,742</b>	1,847
Social hardship donation	1,240	-	<b>1,240</b>	605
Social support	-	12,736	<b>12,736</b>	-
Consultancy service development	-	1,500	<b>1,500</b>	2,100
Subscriptions	2,085	-	<b>2,085</b>	1,800
Telephone	130	6,379	<b>6,509</b>	10,448
Sundry expenses	111	2,109	<b>2,220</b>	1,481
Postage, printing & stationery	110	2,089	<b>2,199</b>	2,716
Rent & service charge	179	8,770	<b>8,949</b>	8,949
Insurance	66	3,225	<b>3,291</b>	3,577
Depreciation - office equipment	4	81	<b>85</b>	257
Support costs:				
Board expenses	6	117	<b>123</b>	100
Accountancy	77	1,473	<b>1,550</b>	2,160
Professional fees	<u>61</u>	<u>1,162</u>	<u><b>1,223</b></u>	<u>13,048</u>
	<u>6,425</u>	<u>224,109</u>	<u><b>230,534</b></u>	<u>235,861</u>

The notes form part of these financial statements

# SICKLE CELL AND THALASSAEMIA SUPPORT PROJECT (WOLVERHAMPTON)

## BALANCE SHEET 31ST MARCH 2024

		2024	2023
	Notes	£	£
<b>Fixed assets</b>			
Tangible assets	4	504	593
<b>Current assets</b>			
Debtors	5	7,190	1,020
Investments	6	52,924	48,607
Cash at bank and in hand		<u>760,334</u>	<u>715,201</u>
		820,448	764,828
<b>Creditors:</b> Amounts falling due within one year	7	<u>(2,840)</u>	<u>(2,160)</u>
<b>Net current assets</b>		<u>817,608</u>	<u>762,668</u>
<b>Total assets less current liabilities</b>		<b>818,112</b>	763,261
<b>Creditors:</b> Amounts falling due within one year	8	<u>85,000</u>	<u>85,000</u>
<b>Net assets</b>		<u><u>733,112</u></u>	<u><u>678,261</u></u>
<b>Income funds</b>			
Unrestricted funds:			
General funds		455,143	348,906
Designated funds		<u>80,000</u>	<u>80,000</u>
		535,143	428,906
Restricted funds		<u>197,969</u>	<u>249,355</u>
<b>Total income funds</b>		<u><u>733,112</u></u>	<u><u>678,261</u></u>

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31st March 2024.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year ended 31st March 2024 in accordance with Section 476 of the Companies Act 2006.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the Board of Trustees on ..... and were signed on its behalf by:

.....  
**L Bell**  
Director/Trustee

.....  
**C R Crosdale**  
Director/Trustee

**Company registration number 03575079**

## **SICKLE CELL AND THALASSAEMIA SUPPORT PROJECT (WOLVERHAMPTON)**

### **NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH 2024**

#### **1. Accounting policies**

##### **Charity information**

Sickle Cell and Thalassaemia Support Project (Wolverhampton) is a private company limited by guarantee incorporated in England and Wales. The registered office is Paycare House, 1st Floor, George Street, Wolverhampton, WV2 4DX. The members of the company are the trustees names on page 1. In the event of the charity being wound up, the liability in respect of the guarantee is limited to £1 per member of the charity.

##### **Accounting convention**

The financial statements have been prepared under the historical cost convention and in accordance with the provisions of Section 1A "Small Entities" of Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", the Charities Act, the Companies Act 2006 and the Statement of Recommended Practice: "Accounting and Reporting by Charities" (FRS 102) with the exception of accounting for the deficit on the defined benefit pension scheme, for which provision has been made as set out below and in note 9.

The financial statements are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £.

##### **Charitable funds**

Unrestricted funds are available for use at the discretion of the trustees in furtherance of their charitable objectives.

Designated funds comprise unrestricted funds that have been set aside by the trustees for particular purposes. The aim and use of each designated fund is set out in the notes to the financial statements.

Restricted funds are subject to specific conditions by donors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.

##### **Income**

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Gifts in kind donated for distribution are included at valuation and recognised as income when they are distributed to the projects. Gifts donated for resale are included as income when they are sold. Donated facilities are included at the value to the charity where this can be quantified and a third party is bearing the cost. No amounts are included in the financial statements for services donated by volunteers.

##### **Expenditure**

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement, and the amount of the obligation can be measured reliably.

Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges are allocated on the portion of the asset's use.

## **SICKLE CELL AND THALASSAEMIA SUPPORT PROJECT (WOLVERHAMPTON)**

### **NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH 2024**

#### **1. Accounting policies (continued)**

All expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all costs related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with use of the resources.

Fund-raising costs are those incurred in seeking voluntary contributions and do not include the costs of disseminating information in support of the charitable activities. Support costs are costs incurred directly in support of expenditure on the objects of the charity and include project management carried out at headquarters. Management and administration costs are those incurred in connection with the administration of the charity and compliance with constitutional and statutory requirements.

#### **Tangible fixed assets**

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Plant and machinery	- 25% on cost
Fixtures and fittings	- 15% & 25% on reducing balance

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in the statement of financial activities.

#### **Investments**

Investments are stated at market value at the balance sheet date. The SOFA includes the net gains or losses arising on revaluation throughout the year.

#### **Pensions**

The company operates a defined benefit pension scheme which provides benefits based on final pensionable pay. The scheme is administered by the West Midlands Pension Fund, and the assets are held independently of the finances of the company. The most recent full actuarial valuation was carried out at 31 March 2022. The projected valuation deficit in the scheme at 31 March 2022 was £512,000 the Board has considered this situation and feels that because of the age of the work force this deficit can be eliminated over a period of time and currently a total provision of £85,000 has been made to date in these accounts.

#### **Restricted Funds**

Monies received as grants for particular purposes are held as separate funds and are credited to the Statement of Financial Activities when costs of the particular relevant projects are incurred.

#### **Leases**

Rentals payable under operating leases, including any lease incentives received, are charged to income on a straight line basis over the term of the relevant lease.



# SICKLE CELL AND THALASSAEMIA SUPPORT PROJECT (WOLVERHAMPTON)

## NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH 2024

### 2. STAFF COSTS

	2024 £	2023 £
Wages and salaries	156,890	159,720
Social security costs	9,663	11,539
Other pension costs	<u>23,724</u>	<u>22,708</u>
	<u>190,277</u>	<u>193,967</u>

The average monthly number of employees during the year was as follows:

	2024	2023
Charitable Workers	<u>5</u>	<u>5</u>

There are no employees who received total emoluments of more than £60,000.

### 3. OPERATING PROFIT/(LOSS)

	2024 £	2023 £
Depreciation - owned assets	<u>89</u>	<u>270</u>
Directors' emoluments and other benefits etc	<u>-</u>	<u>-</u>

### 4. TANGIBLE FIXED ASSETS

	Plant and machinery £	Fixtures and fittings £	Total £
<b>Cost</b>			
At 1st April 2023	23,824	13,391	37,215
Additions	-	-	-
Disposals	<u>-</u>	<u>-</u>	<u>-</u>
At 31st March 2024	<u>23,824</u>	<u>13,391</u>	<u>37,215</u>
<b>Depreciation</b>			
At 1st April 2023	23,824	12,798	36,622
Charge for year	-	89	89
Eliminated on disposals	<u>-</u>	<u>-</u>	<u>-</u>
At 31st March 2024	<u>23,824</u>	<u>12,887</u>	<u>36,711</u>
<b>Net book value</b>			
At 31st March 2024	<u>-</u>	<u>504</u>	<u>504</u>
At 31st March 2023	<u>-</u>	<u>593</u>	<u>593</u>

**SICKLE CELL AND THALASSAEMIA SUPPORT PROJECT (WOLVERHAMPTON)**

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31ST MARCH 2024**

**5. DEBTORS: AMOUNTS FALLING  
DUE WITHIN ONE YEAR**

	<b>2024</b>	<b>2023</b>
	<b>£</b>	<b>£</b>
Prepayments and accrued income	<u><b>7,190</b></u>	<u><b>1,020</b></u>

**6. CURRENT ASSET INVESTMENTS**

	<b>2024</b>	<b>2023</b>
	<b>£</b>	<b>£</b>
Architas MA Passive Moderate S Acc	<u><b>52,924</b></u>	<u><b>48,607</b></u>

**7. CREDITORS: AMOUNTS FALLING  
DUE WITHIN ONE YEAR**

	<b>2024</b>	<b>2023</b>
	<b>£</b>	<b>£</b>
Social security and other tax	-	-
Accruals and deferred income	<u><b>2,840</b></u>	<u><b>2,160</b></u>
	<u><b>2,840</b></u>	<u><b>2,160</b></u>

**8. CREDITORS: AMOUNTS FALLING  
DUE AFTER MORE THAN ONE YEAR**

	<b>2024</b>	<b>2023</b>
	<b>£</b>	<b>£</b>
Provision for defined pension scheme deficit (see note 9)	<u><b>85,000</b></u>	<u><b>85,000</b></u>

**9. PENSION SCHEME**

	<b>2024</b>	<b>2023</b>
	<b>£</b>	<b>£</b>
Value of scheme assets and liabilities		
Market value of assets	<b>820,000</b>	820,000
Present value of scheme liabilities	<u><b>(1,332,000)</b></u>	<u><b>(1,332,000)</b></u>
Pension scheme deficit	<u><b>(512,000)</b></u>	<u><b>(512,000)</b></u>

The above is based on a valuation at 31 March 2022. Provision of £85,000 has been made towards the above deficit.

## SICKLE CELL AND THALASSAEMIA SUPPORT PROJECT (WOLVERHAMPTON)

### NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31ST MARCH 2024

#### 10. OPERATING LEASE COMMITMENTS

At the reporting end date the charity had outstanding commitments for future minimum lease payments under non-cancellable operating leases, which fall due as follows:

	2024 £	2023 £
Within one year	-	-
Between two and five years	<u>-</u>	<u>-</u>
	<u>-</u>	<u>-</u>

#### 11. ANALYSIS OF NET ASSETS BETWEEN FUNDS

	Fixed Assets £	Other Net Assets £	Total Net Assets £
Unrestricted Funds:			
General Funds	-	455,143	455,143
Designated Funds	<u>-</u>	<u>80,000</u>	<u>80,000</u>
	-	535,143	535,143
Restricted Funds	<u>504</u>	<u>197,465</u>	<u>197,969</u>
	<u>504</u>	<u>732,608</u>	<u>733,112</u>

#### 12. RESTRICTED FUNDS

Fund	Purpose of Fund	Reason for Restriction
Wolverhampton CCG	Support the antenatal and newborn screening programme and provide counselling and support to those affected	Wolverhampton residents only
Dudley CCG	Support affected children with long term conditions to manage their condition through various social and community interventions	Dudley residents only
Walsall Healthcare NHS Trust	Support the antenatal and newborn screening programme and provide counselling and support to those affected	Walsall residents only